Efficacy of Topical Finasteride 0.5% vs 17α-Estradiol 0.05% in the Treatment of Postmenopausal Female Pattern Hair Loss: A Retrospective, Single-Blind Study of 119 Patients

Background and Objectives: Female pattern hair loss (FPHL) is a common form of scalp hair loss that occurs in 38% of females. Currently, minoxidil solution is the only therapy approved by the US Food and Drug Administration, but many other treatments are used, including cyproterone acetate, spironol...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Alfredo Rossi, Francesca Magri, Andrea D'Arino, Flavia Pigliacelli, Marta Muscianese, Pierpaolo Leoncini, Gemma Caro, Alessandro Federico, Maria Caterina Fortuna, Marta Carlesimo
Formato:	article
Lenguaje:	EN
Publicado:	Mattioli1885 2020
Materias:	female pattern hair loss topical finasteride 17 α–estriadol minoxidil Dermatology RL1-803
Acceso en línea:	https://doaj.org/article/b1d78e3e6b3a4537b041b1d20fde700c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b1d78e3e6b3a4537b041b1d20fde700c
record_format	dspace
spelling	oai:doaj.org-article:b1d78e3e6b3a4537b041b1d20fde700c2021-11-17T08:28:48ZEfficacy of Topical Finasteride 0.5% vs 17α-Estradiol 0.05% in the Treatment of Postmenopausal Female Pattern Hair Loss: A Retrospective, Single-Blind Study of 119 Patients10.5826/dpc.1002a392160-9381https://doaj.org/article/b1d78e3e6b3a4537b041b1d20fde700c2020-04-01T00:00:00Zhttp://dpcj.org/index.php/dpc/article/view/1075https://doaj.org/toc/2160-9381Background and Objectives: Female pattern hair loss (FPHL) is a common form of scalp hair loss that occurs in 38% of females. Currently, minoxidil solution is the only therapy approved by the US Food and Drug Administration, but many other treatments are used, including cyproterone acetate, spironolactone, topical 17α-estradiol, and prostaglandin analogs. Systemic finasteride has been considered a treatment option in women even though its teratogenic effects tend to limit its prescription. Recently, topical finasteride has been evaluated to limit the side effect profile of the drug. The objective of the present study is to compare retrospectively the efficacy of topical 0.05% 17α-estradiol solution and a 0.5% finasteride lotion in the treatment of FPHL. Patients and Methods: We enrolled 119 postmenopausal female patients. The first group comprised 69 women treated with finasteride 0.5% and minoxidil 2%. The second group included 50 women treated with 17α-estradiol 0.05% and minoxidil 2%. At baseline and at 6- and 12- to 18-month follow-up, global photographs were systematically taken. Three operators blind to the prescribed treatment evaluated photographs using a 7-point scale. One-way analysis of variance and unpaired Student t tests were performed to analyze 7-point scale scores. Results: The improvement was statistically significant from 6 months to 12-18 months, both for finasteride (P < 0.005) and 17α-estradiol (P < 0.05). The efficacy of topical finasteride was significantly greater than that of 17α-estradiol solution, both at the 6-month (P < 0.05) and at the 12- to 18-month follow-up (P < 0.005). In general, the highest improvement was observed after 12-18 months of treatment with topical finasteride therapy. Conclusions: Topical finasteride 0.5% in combination with minoxidil 2% could represent a valid therapeutic option for the treatment of postmenopausal FPHL, showing higher efficacy than topical 17α-estradiol with minoxidil 2% both at 6-month and 12- to 18-month follow-up. Alfredo RossiFrancesca MagriAndrea D'ArinoFlavia PigliacelliMarta MuscianesePierpaolo LeonciniGemma CaroAlessandro FedericoMaria Caterina FortunaMarta CarlesimoMattioli1885articlefemale pattern hair losstopical finasteride17 α–estriadolminoxidilDermatologyRL1-803ENDermatology Practical & Conceptual, Vol 10, Iss 2 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	female pattern hair loss topical finasteride 17 α–estriadol minoxidil Dermatology RL1-803
spellingShingle	female pattern hair loss topical finasteride 17 α–estriadol minoxidil Dermatology RL1-803 Alfredo Rossi Francesca Magri Andrea D'Arino Flavia Pigliacelli Marta Muscianese Pierpaolo Leoncini Gemma Caro Alessandro Federico Maria Caterina Fortuna Marta Carlesimo Efficacy of Topical Finasteride 0.5% vs 17α-Estradiol 0.05% in the Treatment of Postmenopausal Female Pattern Hair Loss: A Retrospective, Single-Blind Study of 119 Patients
description	Background and Objectives: Female pattern hair loss (FPHL) is a common form of scalp hair loss that occurs in 38% of females. Currently, minoxidil solution is the only therapy approved by the US Food and Drug Administration, but many other treatments are used, including cyproterone acetate, spironolactone, topical 17α-estradiol, and prostaglandin analogs. Systemic finasteride has been considered a treatment option in women even though its teratogenic effects tend to limit its prescription. Recently, topical finasteride has been evaluated to limit the side effect profile of the drug. The objective of the present study is to compare retrospectively the efficacy of topical 0.05% 17α-estradiol solution and a 0.5% finasteride lotion in the treatment of FPHL. Patients and Methods: We enrolled 119 postmenopausal female patients. The first group comprised 69 women treated with finasteride 0.5% and minoxidil 2%. The second group included 50 women treated with 17α-estradiol 0.05% and minoxidil 2%. At baseline and at 6- and 12- to 18-month follow-up, global photographs were systematically taken. Three operators blind to the prescribed treatment evaluated photographs using a 7-point scale. One-way analysis of variance and unpaired Student t tests were performed to analyze 7-point scale scores. Results: The improvement was statistically significant from 6 months to 12-18 months, both for finasteride (P < 0.005) and 17α-estradiol (P < 0.05). The efficacy of topical finasteride was significantly greater than that of 17α-estradiol solution, both at the 6-month (P < 0.05) and at the 12- to 18-month follow-up (P < 0.005). In general, the highest improvement was observed after 12-18 months of treatment with topical finasteride therapy. Conclusions: Topical finasteride 0.5% in combination with minoxidil 2% could represent a valid therapeutic option for the treatment of postmenopausal FPHL, showing higher efficacy than topical 17α-estradiol with minoxidil 2% both at 6-month and 12- to 18-month follow-up.
format	article
author	Alfredo Rossi Francesca Magri Andrea D'Arino Flavia Pigliacelli Marta Muscianese Pierpaolo Leoncini Gemma Caro Alessandro Federico Maria Caterina Fortuna Marta Carlesimo
author_facet	Alfredo Rossi Francesca Magri Andrea D'Arino Flavia Pigliacelli Marta Muscianese Pierpaolo Leoncini Gemma Caro Alessandro Federico Maria Caterina Fortuna Marta Carlesimo
author_sort	Alfredo Rossi
title	Efficacy of Topical Finasteride 0.5% vs 17α-Estradiol 0.05% in the Treatment of Postmenopausal Female Pattern Hair Loss: A Retrospective, Single-Blind Study of 119 Patients
title_short	Efficacy of Topical Finasteride 0.5% vs 17α-Estradiol 0.05% in the Treatment of Postmenopausal Female Pattern Hair Loss: A Retrospective, Single-Blind Study of 119 Patients
title_full	Efficacy of Topical Finasteride 0.5% vs 17α-Estradiol 0.05% in the Treatment of Postmenopausal Female Pattern Hair Loss: A Retrospective, Single-Blind Study of 119 Patients
title_fullStr	Efficacy of Topical Finasteride 0.5% vs 17α-Estradiol 0.05% in the Treatment of Postmenopausal Female Pattern Hair Loss: A Retrospective, Single-Blind Study of 119 Patients
title_full_unstemmed	Efficacy of Topical Finasteride 0.5% vs 17α-Estradiol 0.05% in the Treatment of Postmenopausal Female Pattern Hair Loss: A Retrospective, Single-Blind Study of 119 Patients
title_sort	efficacy of topical finasteride 0.5% vs 17α-estradiol 0.05% in the treatment of postmenopausal female pattern hair loss: a retrospective, single-blind study of 119 patients
publisher	Mattioli1885
publishDate	2020
url	https://doaj.org/article/b1d78e3e6b3a4537b041b1d20fde700c
work_keys_str_mv	AT alfredorossi efficacyoftopicalfinasteride05vs17aestradiol005inthetreatmentofpostmenopausalfemalepatternhairlossaretrospectivesingleblindstudyof119patients AT francescamagri efficacyoftopicalfinasteride05vs17aestradiol005inthetreatmentofpostmenopausalfemalepatternhairlossaretrospectivesingleblindstudyof119patients AT andreadarino efficacyoftopicalfinasteride05vs17aestradiol005inthetreatmentofpostmenopausalfemalepatternhairlossaretrospectivesingleblindstudyof119patients AT flaviapigliacelli efficacyoftopicalfinasteride05vs17aestradiol005inthetreatmentofpostmenopausalfemalepatternhairlossaretrospectivesingleblindstudyof119patients AT martamuscianese efficacyoftopicalfinasteride05vs17aestradiol005inthetreatmentofpostmenopausalfemalepatternhairlossaretrospectivesingleblindstudyof119patients AT pierpaololeoncini efficacyoftopicalfinasteride05vs17aestradiol005inthetreatmentofpostmenopausalfemalepatternhairlossaretrospectivesingleblindstudyof119patients AT gemmacaro efficacyoftopicalfinasteride05vs17aestradiol005inthetreatmentofpostmenopausalfemalepatternhairlossaretrospectivesingleblindstudyof119patients AT alessandrofederico efficacyoftopicalfinasteride05vs17aestradiol005inthetreatmentofpostmenopausalfemalepatternhairlossaretrospectivesingleblindstudyof119patients AT mariacaterinafortuna efficacyoftopicalfinasteride05vs17aestradiol005inthetreatmentofpostmenopausalfemalepatternhairlossaretrospectivesingleblindstudyof119patients AT martacarlesimo efficacyoftopicalfinasteride05vs17aestradiol005inthetreatmentofpostmenopausalfemalepatternhairlossaretrospectivesingleblindstudyof119patients
_version_	1718425820363489280

Efficacy of Topical Finasteride 0.5% vs 17α-Estradiol 0.05% in the Treatment of Postmenopausal Female Pattern Hair Loss: A Retrospective, Single-Blind Study of 119 Patients

Ejemplares similares